Venture Management
VC Fund
Madison, United States
Venture Management is a VC fund in Madison focused on Biotechnology and Health Care. Venture Management specializes in seed-stage and startup investments in Wisconsin’s technology arena.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Venture Management invests in
Stages Venture Management invests in
Countries Venture Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Terence F. Kelly
|
|||
Investment Focus
Industry
- Biotechnology 5 (38%)
- Health Care 3 (23%)
- Pharmaceutical 3 (23%)
- Medical 2 (15%)
- Medical Device 2 (15%)
Stage
- Funding Round 4 (31%)
- Series A 3 (23%)
- Seed 2 (15%)
- Debt Financing 2 (15%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Matthew T. Kelly
Vice President
|
Vice President | Total investments: 1 | Find email | |
|
Terence F. Kelly
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Immuto Scientific
|
Immuto Scientific is a biotechnology services company that provides analytical insights to pharmaceutical companies for drug discovery. | $2.3M / Seed / Oct 08, 2021 | |
ParqEx
|
ParqEx is a platform that helps to "unlock" the value of privately owned parking spots, which are often underutilized and/or difficult to manage. The ParqEx Marketplace helps owners to efficiently rent their parking to drivers on an hourly, daily, weekly or monthly basis. For parking spots secured behind gates or garage doors,Access+ is a technology solution that allows owners or managers to grant controlled access through the convenience of the ParqEx app. Finally, GuestParq is a tailored solution to improve the parking experience for guests, tenants, and property managers alike. Learn more at ParqEx.com | $1.3M / Seed / Dec 20, 2016 | |
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $156.5K / Debt Financing / Sep 13, 2016 | |
FluGen
|
FluGen is a biopharmaceutical company specializing on the prevention and treatment of seasonal and pandemic influenza worldwide. | $12M / May 24, 2016 | |
Invenra
|
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies inphenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services.The company was established in 2011 and is based in Madison, Wisconsin, United States. | $4M / May 24, 2016 | |
|
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $1.1M / Mar 17, 2015 | |
Madison Vaccines
|
Madison Vaccines is developing two distinct vaccines for patients with prostate cancer, and a test to identify those patients who will benefit from these vaccines. It is a Delaware C-Corporation operating in Madison, Wisconsin whose principal founders are Douglas McNeel, M.D., Ph.D., and Richard Lesniewski, Ph.D. MVI’s lead vaccine, pTVG-HP, isgiven by a simple intradermal injection, targets a clinically validated target made by prostate tumors known as prostatic acid phosphatase (PAP), and is progressing in a Phase 2 human clinical trial in men who are at very high risk of developing bone metastases after having their cancerous prostate glands removed or irradiated. Early biological and biochemical signals of activity were observed in Phase 1. The company’s second DNA vaccine, pTVG-AR, targets the androgen receptor (AR), a critically important molecule driving prostate cancer growth. pTVG-AR is poised to start clinical trials in early 2014. A novel and potentially proprietary signature in the blood of certain men with prostate cancer has been discovered by the McNeel lab that could become the basis of a companion diagnostic test used to predict which men will respond favorably to MVI vaccines. | $3M / Series A / Mar 10, 2015 | |
Silatronix
|
Silatronix develops organosilicon electrolytes for energy storage devices such as ultracapacitors and lithium-ion batteries. The company's technology combines Dr. West's expertise in organosilicon compounds with that of Dr. Hamers in nanostructured electrodes and electronic properties of materials. It was founded in 2007 andheadquartered in Wisconsin, United States. | $2.1M / Jan 01, 2015 | |
|
FluGen
|
FluGen is a biopharmaceutical company specializing on the prevention and treatment of seasonal and pandemic influenza worldwide. | $3.2M / Debt Financing / May 30, 2014 | |
|
Swallow Solutions
|
The Swallow Solutions website offers help to those with swallowing difficulties, also called dysphagia. There are two parts to dysphagia: diagnostic and treatment devices for swallowing problems, and nutritional food products tailored to a patient's diagnosed level of swallowing difficulty. | $1.4M / Dec 03, 2013 | |
| See all 13 investments → | |||
Co-Investors
Wisconsin Investment Partners
11 deals together
NEW Capital Fund
6 deals together
Venture Investors
4 deals together
Wisconsin Alumni Research Foundation
4 deals together
BrightStar Wisconsin Foundation
2 deals together
Knox Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Venture Management invest in?
Venture Management invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Funding Round and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Venture Management?
Public channels for Venture Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Venture Management?
The team at Venture Management includes Matthew T. Kelly (Vice President) and Terence F. Kelly (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
